Logo

Merck's Keytruda Receives NMPA's Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in China

Share this

Merck's Keytruda Receives NMPA's Approval as Monotherapy for 1L Treatment of Advanced Non-Small Cell Lung Cancer with PD-L1 Tumor Expression in China

Shots:

  • The NMPA approval is based on the P-III KEYNOTE-042 study assessing Keytruda as monothx. vs CT in patients with stage III NSCLC who were not candidates for surgical resection/definitive chemoradiation/mNSCLC with PD-L1 expression & no prior systemic treatment for mNSCLC including data from the extension of KEYNOTE-042 in Chinese patients
  • The extension study results demonstrated improvement in OS in patients whose tumors expressed PD-L1 with a TPS ≥50%- TPS ≥20% and in the entire study population with a TPS ≥1%
  • KEYTRUDA is an anti-PD-1 therapy- act blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first anti-PD-1 therapy to be approved as both monothx. & in combination with CT as 1L treatment for NSCLC in China

Click here to­ read full press release/ article 

Ref: Merck | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions